Effect of Cholesterol on Biomimetic Membrane Curvature and Coronavirus Fusion Peptide Encapsulation

• Published in: ACS nano 2023-05, Vol.17 (9), p.8598-8612
• Main Authors: Milogrodzka, Izabela, Nguyen Pham, Duy Tue, Sama, Gopal R., Samadian, Hajar, Zhai, Jiali, de Campo, Liliana, Kirby, Nigel M., Scott, Timothy F., Banaszak Holl, Mark M., van ‘t Hag, Leonie
• Format: Article
• Language: English
• Subjects: Biomimetics; Cholesterol; Coronavirus; HeLa Cells; Humans; Lipid Bilayers - chemistry; Peptides - chemistry; Peptides - pharmacology; Phospholipids - chemistry
• ISSN: 1936-0851; 1936-086X
• DOI: 10.1021/acsnano.3c01095

Biomimetic cubic phases can be used for protein encapsulation in a variety of applications such as biosensors and drug delivery. Cubic phases with a high concentration of cholesterol and phospholipids were obtained herein. It is shown that the cubic phase structure can be maintained with a higher concentration of biomimetic membrane additives than has been reported previously. Opposing effects on the curvature of the membrane were observed upon the addition of phospholipids and cholesterol. Furthermore, the coronavirus fusion peptide significantly increased the negative curvature of the biomimetic membrane with cholesterol. We show that the viral fusion peptide can undergo structural changes leading to the formation of hydrophobic α-helices that insert into the lipid bilayer. This is of high importance, as a fusion peptide that induces increased negative curvature as shown by the formation of inverse hexagonal phases allows for greater contact area between two membranes, which is required for viral fusion to occur. The cytotoxicity assay showed that the toxicity toward HeLa cells was dramatically decreased when the cholesterol or peptide level in the nanoparticles increased. This suggests that the addition of cholesterol can improve the biocompatibility of the cubic phase nanoparticles, making them safer for use in biomedical applications. As the results, this work improves the potential for the biomedical end-use applications of the nonlamellar lipid nanoparticles and shows the need of systematic formulation studies due to the complex interplay of all components.